Professional Documents
Culture Documents
SUMMARY: The Food and Drug and Drug Administration, 5600 Fishers immunotoxicity testing include the
Administration (FDA) is announcing the Lane, Rockville, MD 20857, 301–827– pharmacology of the drug, intended
availability of a draft guidance entitled 4480. patient population, known drug class
‘‘S8 Immunotoxicity Studies for Human SUPPLEMENTARY INFORMATION:
effects, and retention of the drug in cells
Pharmaceuticals.’’ The draft guidance of the immune system.
was prepared under the auspices of the I. Background This draft guidance is being issued
International Conference on ICH was organized to provide an consistent with FDA’s good guidance
Harmonisation of Technical opportunity for tripartite harmonization practices regulation (21 CFR 10.115).
Requirements for Registration of initiatives to be developed with input This draft guidance, when finalized,
Pharmaceuticals for Human Use (ICH). from both regulatory and industry will represent the agency’s current
The draft guidance describes a weight- representatives. FDA also seeks input thinking on this topic. It does not create
of-evidence approach to determining from consumer representatives and or confer any rights for or on any person
whether additional immunotoxicity others. ICH is concerned with and does not operate to bind FDA or the
testing for nonbiological harmonization of technical public. An alternative approach may be
pharmaceuticals is appropriate when requirements for the registration of used if such approach satisfies the
the findings from standard toxicity pharmaceutical products among three requirements of the applicable statutes
studies indicate signs of regions: The European Union, Japan, and regulations.
immunotoxicity. The draft guidance is and the United States. The six ICH II. Comments
intended to provide recommendations sponsors are the European Commission,
on nonclinical testing to identify Interested persons may submit to the
the European Federation of
compounds that have the potential to be Division of Dockets Management (see
Pharmaceutical Industries Associations,
immunosuppressive and guidance on a ADDRESSES) written or electronic
the Japanese Ministry of Health, Labour,
weight-of-evidence decision making comments on the draft guidance. Two
and Welfare, the Japanese
approach for immunotoxicity testing. copies of mailed comments are to be
Pharmaceutical Manufacturers
DATES: Submit written or electronic submitted, except that individuals may
Association, CDER and CBER (FDA),
comments on the draft guidance by submit one copy. Comments are to be
and the Pharmaceutical Research and
April 11, 2005. General comments on identified with the docket number
Manufacturers of America. The ICH
agency guidance documents are found in brackets in the heading of this
Secretariat, which coordinates the
welcome at any time. document. The draft guidance and
preparation of documentation, is
received comments may be seen in the
ADDRESSES: Submit written requests for provided by the International
Division of Dockets Management
single copies of the draft guidance to the Federation of Pharmaceutical
between 9 a.m. and 4 p.m., Monday
Division of Drug Information (HFD– Manufacturers Associations.
The ICH Steering Committee includes through Friday.
240), Center for Drug Evaluation and
Research (CDER), Food and Drug representatives from each of the ICH III. Electronic Access
Administration, 5600 Fishers Lane, sponsors and the IFPMA, as well as Persons with access to the Internet
Rockville, MD 20857; or the Office of observers from the World Health may obtain the document at http://
Communication, Training and Organization (WHO), Health Canada, www.fda.gov/ohrms/dockets/
Manufacturers Assistance (HFM–40), and the European Free Trade Area. default.htm, http://www.fda.gov/cder/
Center for Biologics Evaluation and In November 2004, the ICH Steering guidance/index.htm, or http://
Research (CBER), Food and Drug Committee agreed that a draft guidance www.fda.gov/cber/publications.htm.
Administration, 1401 Rockville Pike, entitled ‘‘S8 Immunotoxicity Studies for
Rockville, MD 20852–1448. The Human Pharmaceuticals’’ should be Dated: February 1, 2005.
guidance may also be obtained by mail made available for public comment. The Jeffrey Shuren,
by calling the CBER Voice Information draft guidance is the product of the Assistant Commissioner for Policy.
System at 1–800–835–4709 or 301–827– Safety Expert Working Group of the [FR Doc. 05–2418 Filed 2–7–05; 8:45 am]
1800. Send one self-addressed adhesive ICH. Comments about this draft BILLING CODE 4160–01–S
label to assist the office in processing guidance will be considered by FDA
your requests. Submit written comments and the Safety Expert Working Group.
on the draft guidance to the Division of The draft guidance describes a DEPARTMENT OF HEALTH AND
Dockets Management (HFA–305), Food weight-of-evidence approach to HUMAN SERVICES
and Drug Administration, 5630 Fishers determining whether additional
Lane, rm. 1061, Rockville, MD 20852. immunotoxicity testing for Office of Inspector General
Submit electronic comments to http:// nonbiological pharmaceuticals is
appropriate when the findings from Program Exclusions: January 2005
www.fda.gov/dockets/ecomments. See
the SUPPLEMENTARY INFORMATION section standard toxicity studies indicate signs AGENCY: Office of Inspector General,
for electronic access to the draft of immunotoxicity. The draft guidance HHS.
guidance document. provides the following: (1) ACTION: Notice of program exclusions.
FOR FURTHER INFORMATION CONTACT: Recommendations on nonclinical
Regarding the guidance: Kenneth L. testing approaches to identify During the month of January 2005, the
Hastings, Center for Drug compounds which have the potential to HHS Office of Inspector General
Evaluation and Research (HFD– be immunosuppressive and (2) guidance imposed exclusions in the cases set
024), Food and Drug on a weight-of-evidence decision forth below. When an exclusion is
Administration, 5600 Fishers Lane, making approach for immunotoxicity imposed, no program payment is made
Rockville, MD 20857, 301–827– testing. The primary data are from to anyone for any items or services
5922. routine nonclinical toxicology studies (other than an emergency item or
Regarding the ICH: conducted during drug development. service not provided in a hospital
Michelle Limoli, Office of Additional causes for concern that can emergency room) furnished, ordered or
International Programs (HFG–1), Food affect the decision for additional prescribed by an excluded party under
VerDate jul<14>2003 18:12 Feb 07, 2005 Jkt 205001 PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 E:\FR\FM\08FEN1.SGM 08FEN1
Federal Register / Vol. 70, No. 25 / Tuesday, February 8, 2005 / Notices 6699
the Medicare, Medicaid, and all Federal Program beneficiaries remain free to party. The exclusions have national
Health Care programs. In addition, no decide for themselves whether they will effect and also apply to all Executive
program payment is made to any continue to use the services of an Branch procurement and non-
business or facility, e.g., a hospital, that excluded party even though no program procurement programs and activities.
submits bills for payment for items or payments will be made for items and
services provided by an excluded party. services provided by that excluded
PROGRAM-RELATED CONVICTIONS
VerDate jul<14>2003 18:12 Feb 07, 2005 Jkt 205001 PO 00000 Frm 00088 Fmt 4703 Sfmt 4703 E:\FR\FM\08FEN1.SGM 08FEN1
6700 Federal Register / Vol. 70, No. 25 / Tuesday, February 8, 2005 / Notices
LICENSE REVOCATION/SUSPENSION/SURRENDERED
VerDate jul<14>2003 18:12 Feb 07, 2005 Jkt 205001 PO 00000 Frm 00089 Fmt 4703 Sfmt 4703 E:\FR\FM\08FEN1.SGM 08FEN1
Federal Register / Vol. 70, No. 25 / Tuesday, February 8, 2005 / Notices 6701
VerDate jul<14>2003 18:12 Feb 07, 2005 Jkt 205001 PO 00000 Frm 00090 Fmt 4703 Sfmt 4703 E:\FR\FM\08FEN1.SGM 08FEN1
6702 Federal Register / Vol. 70, No. 25 / Tuesday, February 8, 2005 / Notices
Dated: February 1, 2005. Methods for Treating Active Uveitis medication, and subcutaneously
Katherine B. Petrowski, Robert Nussenblatt (NEI) and Thomas administered daclizumab also appeared
Director, Exclusions Staff, Office of Inspector Waldmann (NCI), Zhuqing Li (NEI), to be clinically effective. However,
General. Ronald Buggage (NEI). subjects with active uveitis were less
[FR Doc. 05–2369 Filed 2–7–05; 8:45 am] U.S. Provisional Patent Application No. likely under this regimen to have their
BILLING CODE 4150–04–P 60/616,760 filed 06 Oct 2004 (DHHS disease controlled (J. Autoimmunity
Reference No. E–328–2004/0–US–01). (2003) 21, 283–293).
Licensing Contact: Susan Carson; 301/ The present invention targets patients
DEPARTMENT OF HEALTH AND 435–5020; carsonsu@mail.nih.gov. with refractory, active uveitis and
HUMAN SERVICES Intraocular inflammatory disease consists of a high dose intravenous
(uveitis) is characterized by pain and a induction therapy using daclizumab at
National Institutes of Health two different doses and times followed
decrease in vision that can lead to
by a longer term maintenance therapy.
Government-Owned Inventions; blindness if not treated appropriately.
Positive therapeutic effects have been
Availability for Licensing The incidence and prevalence of the
seen with this protocol in a small group
disease are approximately 52/100,000
of patients within 4–6 weeks after the
AGENCY: National Institutes of Health, and 112/100,000, and this translates
initiation of therapy. As previous work
Public Health Service, DHHS. into an incidence of 151,000 per year
indicated that IL–2R receptors have a
and a prevalence of 322,000. The
ACTION: Notice. slow turnover rate on CD4 positive
numbers are expected to increase as the
subpopulation of lymphocytes, a
population ages. Treatment of severe
SUMMARY: The inventions listed below possible mechanism of action of this
uveitis often focuses on the control of
are owned by an agency of the U.S. new protocol is saturation of CD25
the inflammatory symptoms using high
Government and are available for (TAC) receptors on cells in sequestered
dose corticosteroids, cytotoxic drugs or
licensing in the U.S. in accordance with sites.
other immunosuppressive agents and Available for licensing are methods
35 U.S.C. 207 to achieve expeditious
there is a need for therapies that reduce directed to this treatment of active
commercialization of results of
the major side effects associated with uveitis using a high dose pulsatile
federally-funded research and
the prolonged use of systemic steroids induction protocol of an interleukin-2
development. Foreign patent
(e.g. hyperglycemia, osteoporosis and (Il–2) receptor antagonist. Methods are
applications are filed on selected
loss of immunocompetence). also provided for the treatment of
inventions to extend market coverage Daclizumab is a humanized anti-Tac
for companies and may also be available corneal transplant rejection, limbal stem
(HAT) antibody that specifically binds cell rejection following transplantation,
for licensing. to the alpha subunit (CD25 or Tac optic neuritis and dry eye.
ADDRESSES: Licensing information and subunit) of the human high affinity
copies of the U.S. patent applications interleukin-2 (IL–2) receptor expressed Novel Thermostable Y-Family DNA
listed below may be obtained by writing on the surface of activated lymphocytes. Polymerases
to the indicated licensing contact at the Dr. Nussenblatt and colleagues at the Roger Woodgate (NICHD), John P.
Office of Technology Transfer, National NEI have previously shown that McDonald (NICHD), and Wei Yang
Institutes of Health, 6011 Executive daclizumab can be used to successfully (NIDDK).
Boulevard, Suite 325, Rockville, treat quiescent uveitis. Long term U.S. Provisional Patent Application No.
Maryland 20852–3804; telephone: 301/ daclizumab therapy at a dose of 1mg/kg 60/573,684 filed 20 May 2004 (DHHS
496–7057; fax: 301/402–0220. A signed can be used instead of standard Ref No. E–166–2004/0–US–01); U.S.
Confidential Disclosure Agreement will immunosuppressive agents to treat Provisional Patent Application No.
be required to receive copies of the severe uveitis for more than 4 years with 60/623, 490 filed 29 Oct 2004 (DHHS
patent applications. no adverse effects attributable to the Ref No. E–166–2004/1–US–01).
VerDate jul<14>2003 19:40 Feb 07, 2005 Jkt 205001 PO 00000 Frm 00091 Fmt 4703 Sfmt 4703 E:\FR\FM\08FEN1.SGM 08FEN1